JP2023553094A - 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体 - Google Patents
中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体 Download PDFInfo
- Publication number
- JP2023553094A JP2023553094A JP2023534880A JP2023534880A JP2023553094A JP 2023553094 A JP2023553094 A JP 2023553094A JP 2023534880 A JP2023534880 A JP 2023534880A JP 2023534880 A JP2023534880 A JP 2023534880A JP 2023553094 A JP2023553094 A JP 2023553094A
- Authority
- JP
- Japan
- Prior art keywords
- optionally replaced
- atoms
- formula
- substituted
- available
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122181P | 2020-12-07 | 2020-12-07 | |
| US63/122,181 | 2020-12-07 | ||
| PCT/CA2021/051755 WO2022120475A1 (en) | 2020-12-07 | 2021-12-07 | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553094A true JP2023553094A (ja) | 2023-12-20 |
| JP2023553094A5 JP2023553094A5 (cg-RX-API-DMAC10.html) | 2024-12-06 |
Family
ID=81973031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534880A Pending JP2023553094A (ja) | 2020-12-07 | 2021-12-07 | 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240051978A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4255913A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023553094A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230117597A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116917305A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021394129A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3201080A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL303467A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023006652A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022120475A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| EP4447954A4 (en) * | 2021-12-16 | 2025-12-03 | Icahn School Med Mount Sinai | HETEROCYCLIC COMPOUNDS AS POLARIZED 5HT2A AGONISTS |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| EP4551211A1 (en) * | 2022-07-08 | 2025-05-14 | Institut Curie | Serotonin analogues for use in treating metalloptosis-associated disorders |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789402A (en) * | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| JP2002514642A (ja) * | 1998-05-13 | 2002-05-21 | エリー リリー アンド カンパニー リミテッド | ５−ｈｔ２ａリガンドとしての、及びセロトニン再取り込み抑制剤としてのインドール誘導体 |
| JP2002542241A (ja) * | 1999-04-21 | 2002-12-10 | アレリックス バイオファーマスーティカルス インコーポレーテッド | ５−ｈｔ６親和性を有するピペリジン−インドール化合物 |
| WO2004069828A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| WO2005066157A1 (en) * | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
| JP2010519171A (ja) * | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する化合物 |
| WO2011019738A1 (en) * | 2009-08-10 | 2011-02-17 | Galenea Corporation | Compounds and methods of use thereof |
| WO2022094719A1 (en) * | 2020-11-06 | 2022-05-12 | Pacific Myco Biosciences Ltd. | A method of treating depression by immune modulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| EA200300717A1 (ru) * | 2000-12-22 | 2003-12-25 | Уайт | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов |
-
2021
- 2021-12-07 US US18/265,286 patent/US20240051978A1/en active Pending
- 2021-12-07 JP JP2023534880A patent/JP2023553094A/ja active Pending
- 2021-12-07 AU AU2021394129A patent/AU2021394129A1/en active Pending
- 2021-12-07 KR KR1020237023111A patent/KR20230117597A/ko active Pending
- 2021-12-07 EP EP21901751.4A patent/EP4255913A4/en active Pending
- 2021-12-07 IL IL303467A patent/IL303467A/en unknown
- 2021-12-07 CA CA3201080A patent/CA3201080A1/en active Pending
- 2021-12-07 CN CN202180092982.XA patent/CN116917305A/zh active Pending
- 2021-12-07 MX MX2023006652A patent/MX2023006652A/es unknown
- 2021-12-07 WO PCT/CA2021/051755 patent/WO2022120475A1/en not_active Ceased
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789402A (en) * | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| JP2000512296A (ja) * | 1996-06-14 | 2000-09-19 | イーライ・リリー・アンド・カンパニー | セロトニン再取込み阻害 |
| JP2002514642A (ja) * | 1998-05-13 | 2002-05-21 | エリー リリー アンド カンパニー リミテッド | ５−ｈｔ２ａリガンドとしての、及びセロトニン再取り込み抑制剤としてのインドール誘導体 |
| JP2002542241A (ja) * | 1999-04-21 | 2002-12-10 | アレリックス バイオファーマスーティカルス インコーポレーテッド | ５−ｈｔ６親和性を有するピペリジン−インドール化合物 |
| WO2004069828A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| WO2005066157A1 (en) * | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
| JP2010519171A (ja) * | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する化合物 |
| WO2011019738A1 (en) * | 2009-08-10 | 2011-02-17 | Galenea Corporation | Compounds and methods of use thereof |
| WO2022094719A1 (en) * | 2020-11-06 | 2022-05-12 | Pacific Myco Biosciences Ltd. | A method of treating depression by immune modulation |
Non-Patent Citations (4)
| Title |
|---|
| EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 22(1), JPN6025039599, 1987, pages 33 - 43, ISSN: 0005697599 * |
| HALBERSTADT, ADAM L. ET AL.: "Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administ", PSYCHOPHARMACOLOGY, vol. 221, no. 4, JPN6025015715, 2012, pages 709 - 718, ISSN: 0005697601 * |
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 42(20), JPN6025039598, 1999, pages 4257 - 4263, ISSN: 0005697598 * |
| REGISTRY（STN）[ONLINE]、2017.08.08[検索日 2025.08.27], JPN6025039600, 2017, ISSN: 0005697600 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4255913A1 (en) | 2023-10-11 |
| KR20230117597A (ko) | 2023-08-08 |
| IL303467A (en) | 2023-08-01 |
| CA3201080A1 (en) | 2022-06-16 |
| EP4255913A4 (en) | 2024-11-06 |
| AU2021394129A1 (en) | 2023-07-20 |
| CN116917305A (zh) | 2023-10-20 |
| US20240051978A1 (en) | 2024-02-15 |
| WO2022120475A1 (en) | 2022-06-16 |
| MX2023006652A (es) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7824222B2 (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 | |
| JP2024054193A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| KR20230117597A (ko) | Cns 장애의 치료를 위한 세로토닌성 작용제로서의 3-시클릭아민-인돌 유도체 | |
| JP2024508922A (ja) | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 | |
| AU2022328466A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
| KR20250053094A (ko) | 관련 장애의 치료에 유용한 세로토닌 작용제로서의 인돌린 유도체 | |
| HK40106138A (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| HK40105243A (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| HK40083780A (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20230804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260327 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260727 |